Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy

van Ruth, S ; Hart, A A M ; Bonfrer, J M G ; Verwaal, V J LU and Zoetmulder, F A N (2002) In Annals of Surgical Oncology 9(10). p.961-967
Abstract

BACKGROUND: Tumor markers are useful for diagnosis and follow-up. We studied the prognostic value of baseline and serial carcinoembryonic antigen (CEA) and carbohydrate antigen 19.9 (CA19.9) measurements in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

METHODS: Sixty-three patients with pseudomyxoma peritonei were treated with cytoreductive surgery and HIPEC. The tumor markers CEA and CA19.9 were collected before therapy and at 3-month intervals during follow-up.

RESULTS: Preoperative CEA and CA19.9 levels were increased in, respectively, 75% and 58% of the patients. Baseline tumor marker values were related to the extent of tumor. Immediately... (More)

BACKGROUND: Tumor markers are useful for diagnosis and follow-up. We studied the prognostic value of baseline and serial carcinoembryonic antigen (CEA) and carbohydrate antigen 19.9 (CA19.9) measurements in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

METHODS: Sixty-three patients with pseudomyxoma peritonei were treated with cytoreductive surgery and HIPEC. The tumor markers CEA and CA19.9 were collected before therapy and at 3-month intervals during follow-up.

RESULTS: Preoperative CEA and CA19.9 levels were increased in, respectively, 75% and 58% of the patients. Baseline tumor marker values were related to the extent of tumor. Immediately after HIPEC, both tumor markers decreased markedly (P <.0001). CA19.9 was shown to be a more useful tumor marker than CEA for follow-up. During follow-up, a high absolute CA19.9 level (P =.0005) was predictive for imminent recurrence. Patients who never attained a normal CA19.9 level showed a higher recurrence rate at 1 year (53%; SE, 15%), in comparison to patients who did so (6%; SE 4%). The median lead time of increased CA19.9 to recurrence was 9 months.

CONCLUSIONS: The measurement of the tumor marker CA19.9 is useful in evaluating therapy in patients with pseudomyxoma peritonei treated with cytoreductive surgery and HIPEC. CA19.9 is a prognostic factor for predicting recurrent disease.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
publishing date
type
Contribution to journal
publication status
published
keywords
Analysis of Variance, CA-19-9 Antigen/metabolism, Carcinoembryonic Antigen/metabolism, Disease-Free Survival, Humans, Netherlands/epidemiology, Peritoneal Neoplasms/diagnosis, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Pseudomyxoma Peritonei/diagnosis, Recurrence, Survival Rate
in
Annals of Surgical Oncology
volume
9
issue
10
pages
961 - 967
publisher
Springer
external identifiers
  • scopus:0036897471
  • pmid:12464587
ISSN
1068-9265
DOI
10.1007/BF02574513
language
English
LU publication?
no
id
ecf85046-ca16-49d2-b7ec-4862e3c4caaf
date added to LUP
2022-04-12 10:53:38
date last changed
2024-04-08 20:39:59
@article{ecf85046-ca16-49d2-b7ec-4862e3c4caaf,
  abstract     = {{<p>BACKGROUND: Tumor markers are useful for diagnosis and follow-up. We studied the prognostic value of baseline and serial carcinoembryonic antigen (CEA) and carbohydrate antigen 19.9 (CA19.9) measurements in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).</p><p>METHODS: Sixty-three patients with pseudomyxoma peritonei were treated with cytoreductive surgery and HIPEC. The tumor markers CEA and CA19.9 were collected before therapy and at 3-month intervals during follow-up.</p><p>RESULTS: Preoperative CEA and CA19.9 levels were increased in, respectively, 75% and 58% of the patients. Baseline tumor marker values were related to the extent of tumor. Immediately after HIPEC, both tumor markers decreased markedly (P &lt;.0001). CA19.9 was shown to be a more useful tumor marker than CEA for follow-up. During follow-up, a high absolute CA19.9 level (P =.0005) was predictive for imminent recurrence. Patients who never attained a normal CA19.9 level showed a higher recurrence rate at 1 year (53%; SE, 15%), in comparison to patients who did so (6%; SE 4%). The median lead time of increased CA19.9 to recurrence was 9 months.</p><p>CONCLUSIONS: The measurement of the tumor marker CA19.9 is useful in evaluating therapy in patients with pseudomyxoma peritonei treated with cytoreductive surgery and HIPEC. CA19.9 is a prognostic factor for predicting recurrent disease.</p>}},
  author       = {{van Ruth, S and Hart, A A M and Bonfrer, J M G and Verwaal, V J and Zoetmulder, F A N}},
  issn         = {{1068-9265}},
  keywords     = {{Analysis of Variance; CA-19-9 Antigen/metabolism; Carcinoembryonic Antigen/metabolism; Disease-Free Survival; Humans; Netherlands/epidemiology; Peritoneal Neoplasms/diagnosis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Pseudomyxoma Peritonei/diagnosis; Recurrence; Survival Rate}},
  language     = {{eng}},
  number       = {{10}},
  pages        = {{961--967}},
  publisher    = {{Springer}},
  series       = {{Annals of Surgical Oncology}},
  title        = {{Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy}},
  url          = {{http://dx.doi.org/10.1007/BF02574513}},
  doi          = {{10.1007/BF02574513}},
  volume       = {{9}},
  year         = {{2002}},
}